EXPRESSIVE ARTS THERAPY FOR HOPE IN PEOPLE WITH SCHIZOPHRENIA
EAT-HOPE
The Role of Expressive Arts Therapy in Strengthening Hope in Individuals With Schizophrenia: A Randomized Controlled Trial (EAT-HOPE)
2 other identifiers
interventional
50
1 country
1
Brief Summary
This randomized controlled trial aimed to evaluate the effectiveness of an expressive arts therapy programme based on positive psychotherapy principles in strengthening hope among individuals diagnosed with schizophrenia. Hope is a central component of recovery in schizophrenia, yet structured nursing interventions specifically targeting hope remain limited. The study was conducted with 50 inpatients diagnosed with schizophrenia at a mental health hospital in Türkiye. Participants were randomly assigned to either an intervention group or a control group. The intervention group participated in an eight-session expressive arts therapy programme delivered in small groups, while the control group received standard psychiatric care. Hope levels were assessed before and after the intervention using the Herth Hope Scale. The findings demonstrated that participants who received expressive arts therapy showed significant improvements in overall hope and its key dimensions, including future orientation, positive readiness and expectancy, and connectedness, compared with those receiving standard care. This study suggests that expressive arts therapy may be an effective recovery-oriented nursing intervention to strengthen hope and support psychological recovery in individuals with schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 13, 2026
CompletedFirst Submitted
Initial submission to the registry
March 1, 2026
CompletedFirst Posted
Study publicly available on registry
March 6, 2026
CompletedMarch 10, 2026
March 1, 2026
3 months
March 1, 2026
March 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in Hope Level Measured by the Herth Hope Scale
Hope level will be assessed using the Herth Hope Scale (HHS), a validated 12-item self-report instrument with scores ranging from 12 to 48. Higher scores indicate higher levels of hope.
Baseline and immediately after completion of the intervention (4 weeks)
Herth Hope Scale
Changes in Herth Hope Scale subscale scores (future orientation, positive readiness and expectancy, and interconnectedness) will be evaluated.
Baseline and immediately after completion of the 8-session intervention (approximately 4 weeks)
Secondary Outcomes (1)
Change in Herth Hope Scale Subscale Scores
Baseline and immediately after completion of the intervention
Study Arms (2)
Expressive Arts Therapy Group
EXPERIMENTALParticipants in this arm received an expressive arts therapy programme based on positive psychotherapy principles in addition to standard psychiatric care. The programme consisted of eight structured group sessions delivered face-to-face in small groups. Each session included psychoeducation, creative expression activities such as drawing, collage, and metaphor work, and group sharing. The intervention aimed to strengthen hope and support psychological recovery.
Control Group
NO INTERVENTIONParticipants in this arm received standard psychiatric inpatient care only. Standard care included routine pharmacological treatment, clinical monitoring, and nursing care. No additional psychosocial or expressive arts therapy intervention was provided during the study period.
Interventions
Intervention Description (Kopyalayın) An expressive arts therapy programme based on positive psychotherapy principles was delivered in small groups. The programme consisted of eight structured sessions conducted face-to-face. Each session included psychoeducation, creative expression activities such as drawing, collage, storytelling, and metaphor work, and group sharing. The intervention aimed to strengthen hope, enhance emotional expression, and support psychological recovery in individuals with schizophrenia.
Eligibility Criteria
You may qualify if:
- Diagnosis of schizophrenia according to clinical evaluation
- Age between 18 and 65 years
- Hospitalized in a psychiatric inpatient unit
- At least six months since diagnosis
- Ability to read and understand assessment tools
- Clinically stable without acute psychotic symptoms
- Provided written informed consent
You may not qualify if:
- Severe cognitive impairment
- Acute psychotic symptoms requiring intensive treatment
- Severe physical illness preventing participation
- Refusal to participate or withdrawal of consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
samsun Mental Health Hospital
Atakent, Samsun, 55200, Turkey (Türkiye)
MeSH Terms
Conditions
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- The study was single-blind. The data analyst responsible for statistical analysis was blinded to group allocation. Participants and care providers were not blinded due to the nature of the intervention.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 1, 2026
First Posted
March 6, 2026
Study Start
July 22, 2025
Primary Completion
October 30, 2025
Study Completion
January 13, 2026
Last Updated
March 10, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be publicly shared due to privacy and confidentiality considerations involving a vulnerable psychiatric population. De-identified data may be made available from the principal investigator upon reasonable request and with appropriate ethical approval.